MEDITOPIC represents a brand that uses the latest advances in marine biotechnology to respond to the needs of many of our consumers.
Our significant involvement in the field of dermocosmetic active ingredient research is one of our major assets. In the lab department, a new Barcelona facility was specifically designed to house administrative and manufacturing areas. Inaugurated in 2004, the facility manufactures our products according to Good Manufacturing Practices (GMP) and ISO 22716 certification. Our lab team has over 20 years of experience in cosmetic production and provides our clients with a safety guarantee.
Our research and development (R&D) follows a multidisciplinary approach. By collaborating with private biotech companies and public research institutes, Barcelona has become southern Europe’s most important biomedical research center, from medicinal chemistry to bioengineering. This allows us to monitor the efficacy of new raw materials and stay at the forefront of research into new active ingredients and advanced delivery systems. Most importantly, however, we have access to an advanced development platform in terms of safety and toxicity evaluation.
Marine technology is the result of effective research technologies in marine biodiversity and the application of molecular biology methods to develop active ingredients and end products that offer great skin benefits.
The sea: the greatest source of bioactive metabolites and medications.
The pharmaceutical market is experiencing rapid and continuous growth. However, the demand for the development of new medications keeps going up. The reason for this might be the growing number of drug-resistant infectious diseases and the increasing emergence of new illnesses. Most of our land-based resources have been explored, which is why both academic and private-sector researchers are seeking molecules in the depths of the ocean. Nowadays, marine resources are widely studied for several reasons. Among them is the fact that oceans cover over 70% of the Earth’s surface and of the 36 known living phyla, 34 are found in marine environments, representing more than 300,000+ known species of flora and fauna. Driving the search for active ingredients in the sea is the fact that marine life, both plants and animals, has adapted to a variety of marine environments. These living things are under constant and intense selection pressure, including competition for space, predation, surface degradation, and reproduction.
In the search for new drugs, attention first shifted to the sea in 1970. For example, around 300 patents for natural bioactive marine products were developed between 1969 and 1999. To this date, over 10,000 compounds have been isolated from marine organisms. Only 10% of the over 25,000 plants have been studied in terms of biological activity. The marine environment may be home to over 80% of the world’s plants and animals.
The marine environment is very diverse in terms of temperature, pressure and range of nutrients. This vast variability has allowed for extensive specialization across all phylogenetic levels, particularly among microorganisms. Despite the fact that biodiversity in the marine environment far exceeds that of its terrestrial counterpart, research into the use of naturally derived marine products as pharmaceutical agents is still in its infancy.